Table 3. Gene Expression Changes after TCA Treatment.
Human or mouse hepatocytes were treated with the indicated concentration of taurocholic acid (TCA) and then RT-PCR was used to assess gene changes. No changes were found at 50 or 500 μM TCA treatment in human hepatocytes (data not shown). N=3.
Murine
Hepatocytes | ||
Control | 5000μM TCA | |
mKC | 1.0 ± 0.1 | 25.1 ± 4.6* |
MIP-2 | 1.0 ± 0.1 | 780.0 ± 122.0* |
VCAM-1 | 1.0 ± 0.2 | 3.9 ± 0.2* |
ICAM-1 | 1.0 ± 0.1 | 7.4 ± 0.3* |
TNF-α | 1.0 ± 0.2 | 2.2 ± 0.4* |
Human
Hepatocytes | ||
Control | 5000μM TCA | |
CXCL-1
(mKC) |
1.0 ± 0.4 | 1.3 ± 0.4 |
CXCL-2
(MIP-2) |
1.0 ± 0.4 | 0.8 ± 0.1 |
ICAM-1 | 1.0 ± 0.1 | 1.5 ± 0.4 |
IL-8 | 1.0 ± 0.2 | 2.4 ± 0.4* |
P<0.05 (versus control).
mKC, mouse keratinocyte derived factor; MIP-2, macrophage inflammatory protein 2; VCAM-1, vascular cellular adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; TNF-α, tumor necrosis factor α; CXCL, CXC chemokine motif ligand; IL-8, interleukin-8.